Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

21 Zoekresultaten.

Nerventra Study Adverse event log

- 08-06-16 - 1 Formulier, 4 Itemgroepen, 38 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, Ongoing adverse events, Adverse events log Baseline, Adverse events Visit 1

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Medication log

- 08-06-16 - 1 Formulier, 3 Itemgroepen, 19 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, Medication log, Concomitant medications log

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Sustained increase in EDSS

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, Sustained increase in EDSS

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Termination/Early termination

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, Termination/Early termination

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 10

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 25 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, Safety measurements

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 8

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal

Itemgroepen: Informed Consent and Demography Data, Pasat Summary Score Sheet

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 4

- 08-06-16 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal

Itemgroepen: Demographic Information, 9-Hole Peg test

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Screening - Nerventra Study Sreening

- 06-06-16 - 1 Formulier, 13 Itemgroepen, 192 Data-elementen, 1 Taal

Itemgroepen: Informed Consent and Demography Data, Multiple sclerosis history, Medical history, Safety measurements, Physical examination, FS,Ambulation,EDSS,AI, Timed 25-foot walk, Inclusion criteria, Exclusion criteria, Ancillary studies, Pharmacogenetic information, Subject disposition, Comments

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

NINDS CDE Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis - Magnetic Resonance Imaging

- 14-04-16 - 1 Formulier, 5 Itemgroepen, 319 Data-elementen, 1 Taal

Itemgroepen: Brain Perfusion Magnetic Resonance Imaging, Diffusion Tensor Imaging, Functional Magnetic Resonance Imaging, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy

NINDS Common Data Elements (Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis) Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.